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Abbreviations used: 
13-cis-RA = 13-cis-retinoic acid; 4-oxo-13-cis-RA = 4-oxo-13-cis-retinoic acid; ATRA 
= all-trans retinoic acid; Caco-2 = human endothelial colorectal adenocarcinoma; CD 
= Crohn’s disease; DSS = dextran sodium sulphate; EDTA = 
ethylenediaminetetraacetic acid; FCS = fetal calf serum; FITC = fluorescein 
isothiocyanate; GI = gastrointestinal; GM-CSF = granulocyte-macrophage colony-
stimulating factor; IBD = irritable bowel disease; ICAM-1 = intercellular adhesion 
molecule-1; IFN = interferon; IL = interleukin; IL-1RA, interleukin-1 receptor 
antagonist; ivDCs = in vitro-differentiated human dendritic cells; ivMACs = in vitro-
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differentiated human macrophages; LPS = lipopolysaccharide; MCP = monocyte 
chemotactic protein; MIP = macrophage inflammatory protein; MMP = matrix 
metalloproteinase; TGF = transforming growth factor; THP = monocytic leukemia, 
TNBS = trinitrobenzene sulfonic acid; TNF = tumor necrosis factor; PBMCs = 
peripheral blood mononuclear cells; PBS = phosphate buffered saline; RH = relative 
humidity; UC = ulcerative colitis; VEGF = vascular endothelial growth factor 
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ABSTRACT 
Retinoid treatment is suggested to promote development of inflammatory bowel 
disease, although preclinical studies are not supportive. We evaluated the effect of 
retinoids on cytokine response in in vitro-differentiated human dendritic cells (ivDCs) 
and macrophages (ivMACs) derived from healthy human donors and in cultured 
human THP-1 cells. Effect on human intestinal epithelial cell integrity was also 
assessed. Each cell type was incubated (± lipopolysaccharide [LPS]) with all-trans 
retinoic acid (ATRA), 13-cis-RA (isotretinoin) and 4-oxo-13-cis-RA. Cytokine analysis 
was performed by array analysis. Cultured human endothelial colorectal 
adenocarcinoma (Caco-2) cells were incubated with these retinoids and media 
analyzed for leakage by spectrofluorometric analysis. ATRA consistently and 
significantly inhibited LPS-induced release of the pro-inflammatory cytokines tumour 
necrosis factor, interleukin (IL)-6, macrophage inflammatory protein (MIP)-1α and 
MIP-1β. All retinoids tested stimulated release of the anti-inflammatory cytokines 
granulocyte-macrophage colony-stimulating factor and IL-10, and also monocyte 
chemotactic protein-1, vascular endothelial growth factor and eotaxin-1. Incubation 
with retinoids did not significantly alter the permeability of Caco-2 monolayers. Pre-
treatment of each cell type with retinoids promoted an anti-inflammatory cytokine 
profile with only minimal effect on intestinal epithelial cell permeability; consistent 
with in vivo studies. 
Word count (max 200): 186 
Keywords: cytokines, inflammation in IBD, dendritic cells in IBD, macrophages in 
IBD. 
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1. Introduction 
There is currently much debate as to whether vitamin A and associated 
retinoid derivatives are beneficial or harmful to the gastrointestinal (GI) tract, a 
situation primarily driven by clinical case reports claiming a putative causal 
relationship between retinoid treatment with 13-cis-retinoic acid (13-cis-RA, 
isotretinoin) and the occurrence of ulcerative colitis (UC) and Crohn’s disease (CD), 
i.e. two forms of chronic inflammatory bowel disease (IBD) (Crockett et al., 2010; 
Reddy et al., 2006). Contrary to this, key basic research data do, in fact, support 
anti-inflammatory effects of retinoids on the GI tract (Bai et al., 2009; Iwata and 
Yokata, 2011). Nevertheless, the case for retinoids being beneficial or harmful to the 
GI tract has only infrequently been based on robust scientific evidence and, thus far, 
it has not been possible to confirm or refute a causative relationship (Crockett et al., 
2009). Ideally, further prospective or well-designed retrospective 
pharmacoepidemiological studies are needed to definitively establish causality 
(Rogler et al., manuscript in preparation). 
Understanding of the pathophysiology of IBD has markedly increased recently 
with a number of pre-disposing genetic risk factors identified for CD and (to a lesser 
extent) UC, along with a number of environmental triggers considered as potential 
key mediators of disease development (Rogler, 2011). Although more risk factors 
are expected to follow (Barrett et al., 2008; Latella et al. 2010; Nguyen et al., 2006), 
the role of many these in the pathophysiology of CD, for example, is unclear 
(Mathew, 2008) and, nevertheless, account for only a fraction of observed CD 
incidence (Torkamani et al., 2008). Key environmental triggers include dietary 
factors, food additives or drugs (Cosnes, 2010; Hou et al., 2011a; Hou et al., 2011b; 
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Järnerot et al., 1983; Katschinski  et al., 1988; Martini and Brandes, 1976; Silkoff  et 
al. 1980; Thornton et al., 1979), and cigarette smoking (Avidan  et al., 2005; Cosnes 
et al., 2001; Cosnes et al., 1996; Kane et al., 2005) while psychological factors may 
influence disease course (Cámara et al., 2010; Danese et al., 2004; Levenstein, 
2002). Significantly, the innate immune system and epithelial barrier function are 
critical to the pathophysiology of both UC and CD; thus, environmental triggers that 
influence the intestinal microbiota and modify intestinal barrier function would appear 
particularly relevant. 
Recent studies in experimental models of IBD and in human colonic biopsy 
samples have shown retinoids to be potentially anti-inflammatory; for example, all-
trans-retinoic acid (ATRA, tretinoin) and transforming growth factor (TGF)-1 
promoted differentiation of FOXP3+ regulatory T-cell subsets (Benson et al., 2007; 
Iwata and Yokota, 2011) and prevented differentiation of pro-inflammatory interleukin 
(IL)-17-secreting Th17 cells (Bai et al., 2009; Hundorfean et al., 2012; Nikoopour et 
al., 2008; Reifen et al., 2002). Notably, observations of lower levels of pro-
inflammatory cytokines (tumor necrosis factor [TNF]-α, subsequently referred to as 
TNF, IL-1, IL-17), increased levels of regulatory cytokines (IL-10, TGF-), and a 
dose-dependent amelioration of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced 
colitis by ATRA were sufficiently strong for the authors to suggest ATRA as having 
therapeutic potential in IBD (Bai et al., 2009). Moreover, ATRA has been shown to 
be a critical regulator for barrier protection during mucosal injuries via up-regulation 
of tight-junction proteins and cyclo-oxygenase (Osanai et al., 2007). ATRA has also 
been shown to up-regulate the expression of gut-homing receptors e.g., integrin 
α4β7 and C-C chemokine receptor type 9 on T-cells in vitro, which, upon binding to 
mucosal cascular addresin cell adhesion molecule 1 and chemokine (C-C motif) 
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ligand 25, respectively, mediate the migration of Th17 cells and regulatory T cells to 
the gut mucosa (Iwata et al., 2004). 
Nevertheless, data from studies in primary human cells and intestinal cell 
lines as to the effects of retinoids remain limited. In this in-vitro study we evaluated 
the effects of retinoid derivatives of vitamin A – ATRA (tretinoin, the major metabolic 
derivative of vitamin A), 13-cis-RA (isotretinoin) and 4-oxo-13-cis-retinoic acid (4-
oxo-13-cis-RA, the primary stable metabolite of isotretinoin) – on lipopolysaccharide 
(LPS)-induced cytokine release from differentiated monocytic dendritic cells and 
macrophages, and from cultured human acute monocytic leukaemia (THP)-1 cells, 
and also their effects on human intestinal epithelial cell integrity. The effect of 
retinoids in in vivo animal models has been investigated also (data to be published 
separately). 
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2. Materials and methods 
2.1. Retinoids 
ATRA, 13-cis-RA and 4-oxo-13-cis-RA (RO22-6595, Roche, Switzerland) 
were dissolved in dimethylsulfoxide (40 mg/mL), diluted in phosphate buffered saline 
(PBS), and tested at final concentrations of 0.01–5.0 μg/mL. 
2.2. Human donors 
Peripheral blood from healthy donors (two males and five females, aged 25–
43 years) was obtained after oral consent, and in accordance with the guidelines of 
the ethical committee of Canton Zurich. 
2.3. Isolation of human peripheral blood monocytes 
Peripheral blood mononuclear cells (PBMCs) were isolated from 80 mL of 
peripheral blood according to the Ficoll® gradient centrifugation method. PBMCs 
were incubated with magnetic microbeads (130-091-153, Monocyte Isolation Kit II, 
Miltenyi Biotec, Bergisch Gladbach, Germany) in accordance with the manufacturer’s 
protocol, and final isolation of monocytes was achieved using a magnetic cell sorter 
(AutoMACS, Miltenyi Biotec, Germany). 
2.4. Generation of in vitro-differentiated dendritic cells (ivDCs) 
PBMCs were differentiated into dendritic cells using an established protocol 
(Rogler et al., 1998); monocytes were cultivated in flasks for 1 week under optimal 
conditions (37°C, 5% CO2, 95% relative humidity [RH]) with 5 ng/mL IL-4 and 50 
ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF). 
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2.5. Generation of in vitro-differentiated macrophages (ivMACs) 
As described above for ivDCs, peripheral blood monocytes were differentiated 
into macrophages based on the established protocol cited, with monocytes being 
cultivated in Teflon bags for 1 week under optimal conditions (37°C, 5% CO2, 95% 
RH). Differentiated macrophages were detached from the Teflon bags by incubation 
at 4°C. 
2.6. Cell culture (THP-1 and Caco-2 cells) 
The monocytic/macrophage-like THP-1 cell line was cultivated in Roswell 
Park Memorial Institute medium containing 10% fetal calf serum (FCS), 
supplemented with penicillin (100 U/mL) and streptomycin (100 µg/mL) under 
standard conditions (37°C, 5% CO2, 95% RH). Human epithelial colorectal 
adenocarcinoma (Caco-2) cells were grown in high glucose Dulbecco’s Modified 
Eagle’s Medium containing 10% FCS, supplemented with penicillin (100 U/mL) and 
streptomycin (100 µg/mL) under recommended conditions (37°C, 10% CO2, 95% 
RH). For both cell lines, passaging was carried out according to the guidelines of the 
American Type Culture Collection (ATCC 2012). 
2.7. Stimulation of cytokine response 
The influence of retinoids on the LPS-induced cytokine response of ivDCs, 
ivMACs and THP-1 cells was evaluated in each cell type using the same 
experimental methodology. Primary cells were adjusted to a density of 1×106 
cells/mL and plated onto 96-well plates (100 μL/well). THP-1 cells were incubated in 
six-well plates at a density of 7×105 cells/mL. Retinoids were added to the medium 
(0.01, 0.1, 1.0 and 5.0 μg/mL) for ivDCs, ivMACs and THP-1 cells, and pre-incubated 
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for 1 hour prior to stimulation with LPS (to a final concentration of 100 ng/ml) for a 
further 48 hours at 37°C.  
Incubation medium was collected and processed for cytokine analysis (Rules-
Based Medicine, Austin, Texas, USA) using Human Cytokine MAP A 1.0® array. 
Levels of IL-15 were below the detection limit of the assay and were excluded from 
the analysis. 
For studies in ivDCs, cytokine response data shown are based on at least six 
(LPS-induced) and at least four (no LPS) independently performed experiments, 
each corresponding to a different donor. In ivMACs, these data (both LPS-induced 
and no LPS) were each based on at least four independently performed 
experiments, each corresponding to a different donor. Data shown for cytokine 
response in THP-1 cells are based on three independent experiments. 
2.8. Intestinal epithelial cell permeability 
To investigate a potential role of retinoid derivatives of vitamin A on intestinal 
permeability, the diffusion of fluorescently-labelled dextran was measured across 
Caco-2 monolayers pre-incubated with retinoid. Caco-2 cells were grown onto trans-
well inserts of 0.4 μm pore size for 3 weeks to reach maximum confluency. Cells 
were subsequently pre-incubated with different concentrations of retinoids (0.01, 0.1, 
1.0 and 5.0 μg/mL) for 48 hours. Caco-2 monolayers were washed once with PBS 
and fluorescein isothiocyanate (FITC)-labelled 10 kDA dextran (Sigma-Aldrich, St 
Louis, USA) and added to the apical chambers at a final concentration of 0.2 mg/mL. 
Ethylenediaminetetraacetic acid (EDTA) 0.1 mM was used in parallel as a positive 
control. Following overnight incubation, media from the basal chambers were 
collected and analysed for FITC-dextran leakage using spectrofluorometric analysis 
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(Biotek, Winooski, USA). Data are provided based on mean values from two 
independent representative experiments. 
2.9. Statistical analysis 
Based on a paired analysis of LPS-induced responses, statistical significance 
was determined using a one-way analysis of variance with Tukey’s multi-comparison 
post-test using Graph Pad Prism 5 software (GraphPad Software, La Jolla, 
California, USA). 
Toxicology In Vitro resubmission Text (TIV-D-12-00617) 05 March 2013  
Page 11 
3. Results 
3.1. Cytokine response 
3.1.1. ivDCs 
In the presence of LPS, ATRA significantly inhibited the LPS-induced release 
of pro-inflammatory cytokines such as TNF, IL-6, macrophage inflammatory protein 
(MIP)-1α and MIP-1β from ivDCs (Fig. 1); data were consistent across all retinoid 
concentrations tested (0.01, 0.1, 1.0 and 5.0 μg/mL) and, for clarity, only 1 µg/mL 
data are shown. Additionally, ATRA and its derivatives significantly stimulated the 
production of monocyte chemotactic protein (MCP)-1 and vascular endothelial 
growth factor (VEGF), and also the anti-inflammatory cytokine IL-10 (Fig. 1). 
Although incubation of ivDCs with retinoids affected the LPS-induced release of 
several other cytokine targets implicated in the inflammatory response, none of these 
changes were significant (Supplementary Fig. I).  
In the absence of LPS, incubation with ATRA and 13-cis-RA each induced 
increases in GM-CSF, MCP-1 and VEGF from ivDCs, which were significant at the 
highest doses tested; a similar but non-significant trend being evident for 4-oxo-13-
cis-RA (Fig. 2). There was little or no change in the cytokine response for IL-1α, IL-1 
receptor antagonist (IL-1RA), IL-4, and IL-18. Although there was a tendency for the 
retinoids tested to induce the release of intercellular adhesion molecule-1 (ICAM-1), 
interferon (IFN)-γ, IL-1β, lymphotoxin-α, matrix metalloproteinase (MMP)-2 and stem 
cell factor, and to also inhibit the release of IL-10, IL-6, MIP-1α, MIP-1β and TNF, 
these changes were modest and in all cases not statistically significant 
(Supplementary Fig. II).  
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3.1.2. ivMACs 
In the presence of LPS, similarly significant increases were seen in the 
release of MCP-1, eotaxin-1, and VEGF following incubation of ivMACs with each 
retinoid (Fig. 3, consistent responses were again evident across all retinoid 
concentrations and, for clarity, only 1 µg/mL data are shown). Additionally, significant 
reductions were seen in the LPS-induced release of the pro-inflammatory cytokines 
TNF, IL-6, MIP-1α and MIP-1β (Fig. 3), i.e. responses consistent with those seen for 
ivDCs. Incubation of ivMACs with retinoids also tended to promote increased LPS-
induced release of IL-8, IL-10, IL-1β and IL-1RA and reduction in the release of IL-
1α, but these changes were not statistically significant (Supplementary Fig. III). 
Moreover, no changes were evident in the responses for ICAM-1, IL-18, and MMP-3. 
In the absence of LPS, comparable responses to those observed for ivDCs 
were seen in that the retinoids tested induced the release of MCP-1, eotaxin-1, IL-8 
and VEGF; for eotaxin-1 and VEGF, responses appeared dose dependent (albeit 
non-significant) for all retinoids tested (Fig. 4). There was little or no change in the 
cytokine response for ICAM-1, IL-1α, IL-1β, and IL-6. Although there was a tendency 
for the retinoids tested to induce the release of IL-10, IL-18 and MIP-1α as well as 
inhibit the release of pro-inflammatory IFN-γ, IL-1RA, MIP-1β, MMP-3 and TNF, 
these changes were modest and in all cases not statistically significant 
(Supplementary Fig. IV).  
3.1.3. THP-1 cells 
The effects of retinoids on LPS-induced cytokine response from THP-1 cells 
were generally similar to those observed for both ivDCs and ivMACs. Pre-incubation 
of THP-1 cells with retinoids resulted in reduced LPS-induced release of IL-6 and 
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increased release of IL-8 and to a minor extent -MCP-1; these responses were 
evident for each of the retinoids tested (Fig. 5) and generally consistent with 
responses seen in ivDCs and ivMACs (Figs. 1–4). 
3.2. Intestinal permeability 
Incubation of human Caco-2 cells with different concentrations each of ATRA, 
isotretinoin and 4-oxo-cis-RA resulted in no significant change in permeability of 
Caco-2 monolayers at all doses tested (Supplementary Fig. V). FITC-labeled dextran 
was observed to be translocated effectively in EDTA-treated monolayers, a finding 
consistent with the known potent adverse effect of this compound on tight-junction 
integrity (Tomita et al., 1994). 
Toxicology In Vitro resubmission Text (TIV-D-12-00617) 05 March 2013  
Page 14 
4. Discussion 
Retinoid treatment has recently been suggested to play a pathophysiological 
role in the development of chronic IBD, a contention based essentially on several 
case reports (Crockett et al., 2009; Shale et al., 2009). However, key basic research 
data appear to contradict this in showing retinoids to be mainly associated with anti-
inflammatory activity (Bai et al., 2009; Straus and Glass, 2007) and, for example, 
substitution of vitamin A in a TNBS rat model of colitis was found to ameliorate colitis 
according to histological scores and weight curves (Bai et al., 2009; Reifen et al., 
2002). While the molecular effects of vitamin A and its retinoid derivatives are well 
understood based on studies in multiple in-vitro settings (Amann et al., 2011; 
Delacroix et al., 2010; Li et al., 2006; Norris et al., 1987; Wada et al., 2009), the data 
available from intestinal cell lines and primary human cells are generally limited; a 
situation that has led to speculation recently as to whether retinoids are harmful or 
beneficial to the GI tract (Crockett et al., 2010; Reddy et al., 2006), and suggested 
need for further study (Rogler et al., 2012, unpublished observation, manuscript in 
preparation). 
The findings from this in vitro study, designed to evaluate the effect of 
retinoids on cytokine release and suppression, and GI integrity in various human 
immune cell types, clearly demonstrate that pre-treatment of ivDCs, ivMACs and 
cultured human THP-1 cells with ATRA, or the derivatives tested, promotes an anti-
inflammatory pattern of cytokine release with little or no change in epithelial cell line 
integrity. This specifically relates to significant inhibition of LPS-induced release of 
pro-inflammatory cytokines such as TNF and IL-6, and also of MIP-1α and MIP-1β. 
These observations, and also the fact that all retinoids tested stimulated the release 
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of the anti-inflammatory cytokine IL-10 from ivMACs and ivDCs, collectively confirm 
that retinoids promote a pattern of cytokine release that is more anti-inflammatory 
than pro-inflammatory. Such a pattern is, in fact, consistent with recent in vitro and in 
vivo studies. For example, retinoids such as ATRA play a crucial role in the 
differentiation of T-cells by inducing the differentiation of gut-homing FOXP3+ 
regulatory T-cells and preventing the differentiation of pro-inflammatory IL-17-
secreting Th17 cells (including in human colonic biopsies) (Bai et al., 2009; Iwata 
and Yokota, 2011); they also promote the homing of Th17 cells and regulatory T 
cells to the GI mucosa and stimulation of antigen-presenting cells to secrete IL-10 
(Benson et al., 2007; Crockett et al., 2009; Hundorfean et al., 2012; Nikoopour et al., 
2008). Additionally, ATRA treatment has been shown to reduce inflammation, 
mucosal damage and myeloperoxidase activity in the mouse TNBS colitis model. In 
this study, lamina propria mononuclear cells from ATRA-treated animals were 
reported to produce lower levels of pro-inflammatory TNF, IL-1β, and IL-17 and 
release more regulatory cytokines (IL-10 and TGF-β) (Bai et al., 2009). 
In the absence of LPS, incubation with each of the retinoids tested was 
similarly associated with little, or no, effect on the release of inflammatory mediators 
from all cell types; an effect that was observed over a broad range of retinoid 
concentrations (0.01, 0.1, 1.0 and 5 μg/mL). Under these conditions, the retinoids 
tested induced the release of eotaxin-1, MCP-1 and IL-8, i.e. chemokine targets 
involved in the migration of immune cells, and also GM-CSF and VEGF, from ivDCs 
and ivMACs. Perhaps most notable is the markedly increased release of GM-CSF, 
MCP-1 and VEGF in response to retinoids alone. There is now strong evidence, 
including studies both in GM-CSF knockout mice (Xu et al., 2008) and in human 
subjects (Goldstein et al., 2011), to support a key role of GM-CSF in activating and 
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maintaining intestinal innate immune barrier function. Collectively, such findings have 
fostered the emergence of CSFs as a potential tool for the treatment of IBD 
(Barahona-Garrido and Yamamoto-Furusho, 2008) and, in fact, recent controlled 
clinical trials have shown treatment with recombinant human GM-CSF to decrease 
disease severity and improve the quality of life of patients with active CD (Goldstein 
et al., 2011; Korzenik et al., 2005). It follows, therefore, that the retinoid-induced 
release of GM-CSF reported here, as distinct from LPS-induced responses, would 
provide potential benefit to the GI environment, particularly in pathological states 
such as IBD. 
A similar view could be taken regarding the observed changes in MCP-1. This 
key target, together with IL-10, is crucial for the regulation of immune responses 
against commensal bacteria by intestinal macrophages (Takada et al., 2010) and 
has been shown also to exert a beneficial effect on dextran sodium sulphate (DSS)-
induced colitis in mice (Maharshak et al., 2010). Thus, as for GM-CSF, the retinoid-
induced release of MCP-1 seen in this study, both in the presence and absence of 
LPS, may similarly preclude a beneficial effect of this chemokine in steady-state gut 
homeostasis. In contrast, however, overexpression of VEGF-A has been shown to 
be associated with deterioration in disease status in mice with DSS-induced colitis, 
levels correlating with increased angiogenesis and leukocyte adhesion in the 
intestine (Scaldaferri et al., 2009), while increased levels of VEGF are usually 
observed in human subjects with IBD (Tsiolakidou et al., 2008). The release of 
VEGF might, therefore, be expected to convey potentially negative effects on 
intestinal immunology. To counterbalance this argument, VEGF has also been 
observed to inhibit the apoptosis of intestinal epithelial cells – thus preventing 
bacterial translocation across ileal mucosa (Nakajima et al., 2007) – while levels of 
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VEGF expression are reported as not being associated with disease activity in 
patients with IBD (Alkim et al. 2012). Nevertheless, until more data become available 
relating to the effect of VEGF on maintenance of gut homeostasis, it is perhaps 
prudent that caution is exercised in assessing the overall effect of this cytokine target 
on the intestinal milieu. 
All retinoids tested were also found to have little or no adverse effect on the 
permeability of Caco-2 monolayers. This was also evident at all doses tested and is 
in apparent conflict with a relatively early in vitro study, which showed that the 
permeability of the Caco-2 monolayer, as measured by transepithelial electric 
resistance and [3H]-mannitol flux, was enhanced by ATRA. Given the known 
association between vitamin A deficiency and impairment in intestinal integrity, the 
authors considered this surprising and attributed increased permeability to an 
unknown mechanism(s) and not altered tight-junction protein expression (Baltes et 
al., 2004). The findings with regard to permeability are, however, consistent with 
reported protective effects of retinoids for the GI mucosa. For example, gastric 
mucosal protection (against indomethacin treatment) was seen in healthy persons 
and in patients with gastric ulcer and duodenal ulcer without any inhibition of gastric 
acid secretion (Mózsik et al., 2001), while increased mucin production in the 
presence of retinoids was considered to contradict any putative drying effect of 
retinoid analogues on the intestinal epithelium as a causal contributor of IBD (Gray et 
al., 2001; Tan et al., 2007). 
In summary, these in vitro findings confirm that retinoid derivatives of vitamin 
A provoke an LPS-induced cytokine response from human immune cells consistent 
with an anti-inflammatory pattern and with little or no adverse effect on intestinal 
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epithelial permeability. As such, these studies do not support retinoids as presenting 
a metabolic milieu dangerous to the GI tract. These findings are consistent with 
studies in in vivo animal models of colitis (to be published separately). 
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Fig. 1. The influence of retinoids on LPS-induced release of inflammatory targets 
from ivDCs 
 
Cell-treated supernatants were analyzed for different cytokines and chemokines after 
incubation with retinoids (1 μg/mL) and stimulation with LPS (100 ng/mL). Bars 
represent mean +SEM values from at least six independent experiments 
corresponding to different donors. 
*P < 0.05; ***P < 0.001 
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Fig. 2. The influence of retinoids on the release of inflammatory targets from ivDCs 
 
Cell-treated supernatants were analyzed for different cytokines and chemokines after 
incubation with different concentrations of retinoids (0.01, 0.1, 1.0 and 5.0 μg/mL). 
Bars represent mean +SEM values from at least four independent experiments 
corresponding to different donors. 
*P < 0.05; **P < 0.01; ***P < 0.001 
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Fig. 3. The influence of retinoids on LPS-induced release of inflammatory targets 
from ivMACs 
 
Cell-treated supernatants were analyzed for different cytokines and chemokines after 
incubation with retinoids (1 μg/mL) and stimulation with LPS (100 ng/mL). Bars 
represent mean +SEM values from at least four independent experiments 
corresponding to different donors. 
*P < 0.05; **P < 0.01; ***P < 0.001 
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Fig. 4. The influence of retinoids on the release of inflammatory targets from ivMACs 
 
Cell-treated supernatants were analyzed for different cytokines and chemokines after 
incubation with different concentrations of retinoids (0.01, 0.1, 1.0 and 5.0 μg/mL). 
Bars represent mean +SEM values from at least four independent experiments 
corresponding to different donors. 
*P < 0.05; **P < 0.01; ***P < 0.001 
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Fig. 5. The influence of retinoids on the release of inflammatory targets from THP-1 
cells 
 
Cell-treated supernatants were analyzed for different cytokines and chemokines after 
incubation with different concentrations of retinoids (0.01, 0.1, 1.0 and 5.0 μg/mL) 
either in the absence (light bars) or presence (dark bars) of LPS (1 µg/mL). Bars 
indicate mean values from three independent experiments. 
 
